Sun Pharma planned INR 150 billion debt issue: what it means for Sun Pharma stock

Published on 10/12/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sun Pharma stock faces an INR 150.00 billion debt proposal dated October 7, 2026. Q1 fiscal 2027 revenue rose 10.10 percent to INR 153.00 billion.

Sun Pharma planned an INR 150.00 billion non-convertible debenture issue for board consideration on October 12, 2026.
Q1 fiscal 2027 revenue rose 10.10 percent to INR 153.00 billion, while net profit reached INR 28.95 billion.
The NSE close was INR 1,760.00 on October 9, 2026, with a 52-week range of INR 1,583.70 to INR 2,046.90.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (INE044A01036) had planned an INR 150.00 billion non-convertible debenture issue for board consideration on October 12, 2026. As AirNews.in reported on October 7, 2026, the proposed securities would be listed, rated, unsecured and redeemable, with private placement in one or more tranches.

Three dated milestones

On July 7, 2026, Sun Pharma reported fiscal 2026 sales of INR 582.00 billion and an EBITDA margin of 30.30 percent, according to ALFA Finder.

On July 31, 2026, Q1 fiscal 2027 revenue reached INR 153.00 billion, up 10.50 percent year over year, while net profit rose 27.00 percent to INR 28.95 billion, the same source reported. The October 7 debt proposal is the latest dated financing step in this sequence.

Why the debt matters

The proposed amount equals a material funding decision against Sun Pharma's operating scale. The company generated INR 153.00 billion of revenue in the first quarter of fiscal 2027, while the planned issue would add financing capacity for strategic needs.

Market context is equally important. Sun Pharma closed at INR 1,760.00 on the NSE on October 9, 2026, and its 52-week range was INR 1,583.70 to INR 2,046.90.

What does the issue mean?

The answer depends on the final coupon, maturity and use of proceeds. The October 7 report said the board would consider listed, rated, unsecured and redeemable debentures, but the maximum proposed amount was the only quantified size disclosed in the source.

That structure gives Sun Pharma access to institutional funding while leaving the eventual interest burden dependent on terms approved by the board. For investors, the key comparison is between the INR 150.00 billion financing plan and the company's recent earnings base of INR 28.95 billion in quarterly net profit.

Next dates and stock levels

The board consideration date was October 12, 2026, according to Kotak Neo. The latest reported interim period was the first quarter of fiscal 2027, ended June 30, 2026, and the company investor page lists the quarter's financial results and earnings materials.

Sun Pharma's NSE close of INR 1,760.00 on October 9, 2026 stood INR 286.90 below its 52-week high of INR 2,046.90 and INR 176.30 above its 52-week low of INR 1,583.70. The dated market levels frame the financing decision without turning it into an investment recommendation.